The performance of the stock price over the year has been up and down, leaving investors with either an optimistic or pessimistic outlook, depending on how they interpret the data. The index has shown a price loss of -14.19% this year. Over the last six months, there has been a stronger performance of -39.39%. The price of ZNTL leaped by -15.86% during the last 30 days period. For the last 5-days stocks have slided -6.47%.
The market performance of Zentalis Pharmaceuticals Inc’s stock has been turbulent in recent times. Over the last year, the company’s stock reached its highest point at $18.07 on 02/28/24, while the lowest value for the same duration was $2.41 on 01/14/25.
52-week price history of ZNTL Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Zentalis Pharmaceuticals Inc’s current trading price is -85.61% away from its 52-week high, while its distance from the 52-week low is 7.88%. The stock’s price range during this period has varied between$2.41 and $18.07. The Zentalis Pharmaceuticals Inc’s shares, which operate in the Healthcare, saw a trading volume of around 0.89 million for the day, a figure considerably lower than their average daily volume of 1.33 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Zentalis Pharmaceuticals Inc (ZNTL) has experienced a quarterly decline of -11.56% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 185.29M and boasts a workforce of 168 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 3.30, with a change in price of -0.47. Similarly, Zentalis Pharmaceuticals Inc recorded 1,756,682 in trading volume during the last 100 days, posting a change of -15.26%.
ZNTL’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for ZNTL stands at 0.12. Similarly, the long-term debt-to-equity ratio is also 0.11.
ZNTL Stock Stochastic Average
Zentalis Pharmaceuticals Inc’s raw stochastic average for the past 50 days is presently 9.85%, as of today. This marks a decrease from the raw stochastic average of the last 20 days, which was 21.74%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 31.70% and 23.75%, respectively.
